Zhicang Ye - 1Hangzhou DAC Biotechnology Co., Ltd.

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 8 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Abstract 5821: DXC008, a novel STEAP1 antibody-tubulysin analog conjugate with a function linker, demonstrates a potential to broaden therapeutic opportunities for prostate tumors

Qingliang Yang,Yuanyuan Huang,Junxiang Jia,Huihui Guo, Lingli Zhang,You Zhou,Zhicang Ye,Hangbo Ye,Yifang Xu, WenJun Li, Zhiyu Zhao, Lingyao Zhao, Lu Bai, Jun Zheng,Robert Y. Zhao

Cancer Researchno. 6_Supplement (2024): 5821-5821

Cited0Views0Bibtex

Abstract 1883: A MUC1 Antibody-Conjugated with a Tubulysin B Analog, DXC005, Demonstrates Excellent Synergistic Effect in Combination with Gemcitabine for Treatment of Pancreatic Tumors

Xiaobo Cai, Min Cao,Huihui Guo,Qingliang Yang,Yongxiang Chen,Xiangfei Kong,Yong Du,Zhicang Ye,Zhixiang Guo,Lingli Zhang,Lu Bai,Junxiang Jia,Yunxia Zheng,Wei Zheng,Jun Zheng,Wenjun Li,Yuanyuan Huang,Zhongliang Fan,Binbin Chen, Yanlei Yang,Meng Dai,Robert Y. Zhao

Cancer Researchno. 6_Supplement (2024): 1883-1883

Cited0Views0Bibtex

Abstract 4553: DXC004A, a novel EGFR antibody-tubulysin analog conjugate demonstrated potential to broaden therapeutic opportunities for non-small cell lung cancer

Cancer Researchno. 6_Supplement (2024): 4553-4553

Cited0Views0Bibtex

Abstract 6581: DX126-262 combined with chemotherapy (Cisplatin and 5-Fu) demonstrates promising antitumor efficacy in HER2-positive gastric cancer

Cancer Researchno. 6_Supplement (2024): 6581-6581

Cited0Views0Bibtex

Abstract 5819: an Anti-Trop2-cpt113 ADC, Exhibits Potent Targeted Antitumor Activity and Favorable Pharmacokinetic Properties

Cancer Researchno. 6_Supplement (2024): 5819-5819

Cited0Views0Bibtex

Abstract 1882: DXC024, a novel anti-TROP2/EGFR bispecific antibody and tubulysin conjugate, for targeted treatment of highly TROP2- or EGFR-expressing tumors

Cancer Researchno. 6_Supplement (2024): 1882-1882

Cited0Views0Bibtex

Abstract 1884: DXC006, Anti-CD56-CPT113 ADC Displays Favorable Anti-Tumor Efficacy, Pharmacokinetic and Safety Profiles in Preclinical Studies

Cancer Researchno. 6_Supplement (2024): 1884-1884

Cited0Views0Bibtex

Abstract 3147: DXC025, a Novel Anti-Muc1/egfr Bispecific Antibody-Tubulysin Conjugate with a Function Linker, Exhibits Potent Anti-Tumor Efficacy

Xingyan Jiang,Junxiang Jia,Huihui Guo,Xiangfei Kong, Yongfang Xu, Sishi Ye,Yong Du,Zhicang Ye, Qikuang Cen,Lingli Zhang,Yongxiang Chen, Gaituo Chen,Lu Bai,Yunxia Zheng,Wei Zheng,Jun Zheng,Juan Wang,Wenjun Li,Yuanyuan Huang,Linyao Zhao,Yifang Xu,Mengmeng Liu,Binbin Chen,Meng Dai,Miaomiao Chen,Zhixiang Guo,Qingliang Yang,Robert Y. Zhao

Cancer Researchno. 6_Supplement (2024): 3147-3147

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn